Cantab Capital Partners Llp Has Boosted Its American Express Co. Cmn (AXP) Position; Alexion Pharmaceuticals (ALXN) Sentiment Is 1.17

February 25, 2018 - By Richard Conner

Cantab Capital Partners Llp increased American Express Co. Cmn (AXP) stake by 184.68% reported in 2017Q3 SEC filing. Cantab Capital Partners Llp acquired 615 shares as American Express Co. Cmn (AXP)’s stock declined 3.65%. The Cantab Capital Partners Llp holds 948 shares with $86.00M value, up from 333 last quarter. American Express Co. Cmn now has $85.00 billion valuation. The stock increased 1.49% or $1.45 during the last trading session, reaching $98.8. About 2.44 million shares traded. American Express Company (NYSE:AXP) has risen 22.41% since February 25, 2017 and is uptrending. It has outperformed by 5.71% the S&P500.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company has market cap of $26.37 billion. The firm offers Soliris , a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It has a 60.37 P/E ratio. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency.

Investors sentiment increased to 0.83 in Q3 2017. Its up 0.01, from 0.82 in 2017Q2. It increased, as 47 investors sold AXP shares while 434 reduced holdings. 100 funds opened positions while 297 raised stakes. 709.03 million shares or 0.92% less from 715.61 million shares in 2017Q2 were reported. Thompson Siegel Walmsley Ltd Com holds 85,048 shares or 0.09% of its portfolio. Blue Finance Cap reported 0.35% stake. Asset Advsr Corp holds 2,300 shares or 0.04% of its portfolio. Canandaigua Bank Tru reported 14,932 shares. Fayez Sarofim & reported 2.26M shares. Meyer Handelman holds 0.15% or 37,410 shares. Da Davidson And Co stated it has 0.05% of its portfolio in American Express Company (NYSE:AXP). Gfs Advsr Ltd Limited Liability Company stated it has 0.64% in American Express Company (NYSE:AXP). Troy Asset Mgmt Limited invested in 6.54% or 1.60M shares. Nichols & Pratt Advisers Llp Ma reported 0.02% of its portfolio in American Express Company (NYSE:AXP). Signalpoint Asset Mgmt Limited stated it has 0.13% of its portfolio in American Express Company (NYSE:AXP). Comerica stated it has 0.05% of its portfolio in American Express Company (NYSE:AXP). Next Group Incorporated Inc stated it has 25,312 shares. Peak6 Ltd Partnership, a Illinois-based fund reported 128,952 shares. Citadel Limited Liability Corp stated it has 1.68M shares or 0.12% of all its holdings.

Cantab Capital Partners Llp decreased Firstenergy Corp Cmn (NYSE:FE) stake by 8,177 shares to 10,292 valued at $317.00 million in 2017Q3. It also reduced Hancock Holding Co Cmn (NASDAQ:HBHC) stake by 18,008 shares and now owns 547 shares. Domino’s Pizza Inc. Cmn (NYSE:DPZ) was reduced too.

Since September 7, 2017, it had 0 insider purchases, and 11 selling transactions for $35.65 million activity. 56,680 shares valued at $5.63M were sold by Gupta Ashwini on Tuesday, December 12. Bush James Peter also sold $1.27M worth of American Express Company (NYSE:AXP) shares. The insider Zukauckas Linda sold 3,196 shares worth $304,962. Buckminster Douglas E. sold $8.79 million worth of stock or 88,930 shares. $506,340 worth of American Express Company (NYSE:AXP) was sold by Sobbott Susan on Thursday, September 7. CHENAULT KENNETH I sold 96,440 shares worth $9.38M. On Wednesday, October 25 the insider Williams Anre D sold $2.87M.

Among 36 analysts covering American Express Company (NYSE:AXP), 11 have Buy rating, 4 Sell and 21 Hold. Therefore 31% are positive. American Express Company had 108 analyst reports since July 23, 2015 according to SRatingsIntel. On Thursday, October 22 the stock rating was maintained by Credit Suisse with “Underperform”. RBC Capital Markets maintained it with “Underperform” rating and $59 target in Friday, January 22 report. On Thursday, October 20 the stock rating was upgraded by Bank of America to “Neutral”. On Thursday, January 11 the stock rating was maintained by Barclays Capital with “Hold”. The firm has “Buy” rating by Keefe Bruyette & Woods given on Friday, September 22. The stock of American Express Company (NYSE:AXP) has “Neutral” rating given on Wednesday, January 13 by Goldman Sachs. The rating was maintained by Goldman Sachs on Friday, April 21 with “Neutral”. The company was maintained on Thursday, April 21 by Goldman Sachs. On Thursday, July 20 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The stock has “Equal-Weight” rating by Morgan Stanley on Thursday, April 21.

Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on April, 26. They expect $1.28 EPS, up 6.67% or $0.08 from last year’s $1.2 per share. ALXN’s profit will be $283.76M for 23.23 P/E if the $1.28 EPS becomes a reality. After $1.28 actual EPS reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Since January 1, 0001, it had 0 insider purchases, and 13 sales for $5.11 million activity.

Baker Bros. Advisors Lp holds 9.73% of its portfolio in Alexion Pharmaceuticals, Inc. for 8.55 million shares. Palo Alto Investors Llc owns 1.08 million shares or 6.38% of their US portfolio. Moreover, Tourbillon Capital Partners L.P. has 5.35% invested in the company for 1.58 million shares. The Switzerland-based Bb Biotech Ag has invested 5.26% in the stock. Orbimed Advisors Llc, a New York-based fund reported 3.65 million shares.

The stock increased 3.79% or $4.34 during the last trading session, reaching $118.93. About 1.82 million shares traded. Alexion Pharmaceuticals, Inc. (ALXN) has declined 18.12% since February 25, 2017 and is downtrending. It has underperformed by 34.82% the S&P500.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: